acquired
Stage
1
Investors
About
Orbital Therapeutics was a preclinical circular RNA (circRNA) platform company developing next-generation therapies and vaccines targeting rare disease, oncology, and immunology. The company was acquired by Bristol Myers Squibb for $1.5B.
Explore Orbital Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.